Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS44002456HTLV-1ENSG00000047936.11protein_codingROS1YesNo6098P08922
TVIS44001078HTLV-1ENSG00000047936.11protein_codingROS1YesNo6098P08922
TVIS44028962HTLV-1ENSG00000047936.11protein_codingROS1YesNo6098P08922
TVIS44014479HTLV-1ENSG00000047936.11protein_codingROS1YesNo6098P08922
TVIS44025629HTLV-1ENSG00000047936.11protein_codingROS1YesNo6098P08922
TCGA Plot Options
Drug Information
GeneROS1
DrugBank IDDB11986
Drug NameEntrectinib
Target IDBE0009534
UniProt IDP08922
Regulation Typeinhibitor
PubMed IDs30050303; 26457764; 26939704; 30425456
CitationsLiu D, Offin M, Harnicar S, Li BT, Drilon A: Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Ther Clin Risk Manag. 2018 Jul 20;14:1247-1252. doi: 10.2147/TCRM.S147381. eCollection 2018.@@Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Russo A, Passiglia F, Giallombardo M, Peeters M, Raez L: Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. Expert Opin Investig Drugs. 2015;24(11):1493-500. doi: 10.1517/13543784.2015.1096344. Epub 2015 Oct 12.@@Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A: Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Mol Cancer Ther. 2016 Apr;15(4):628-39. doi: 10.1158/1535-7163.MCT-15-0758. Epub 2016 Mar 3.@@Pacenta HL, Macy ME: Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma. Drug Des Devel Ther. 2018 Oct 23;12:3549-3561. doi: 10.2147/DDDT.S147384. eCollection 2018.
GroupsApproved; Investigational
Direct ClassificationPhenylpiperazines
SMILESCN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C23)C(NC2CCOCC2)=C1
Pathways
PharmGKB
ChEMBLCHEMBL1983268